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Abstract 
Background Obesity and asthma have increased in westernised countries. Maternal obesity 
may increase childhood asthma risk. If this relation is causal it may be mediated through 
factors associated with maternal adiposity, such as fetal development, pregnancy 
complications or infant adiposity. We investigated the relationships of maternal BMI and fat 
mass with childhood wheeze and examined the influences of infant weight gain and 
childhood obesity. 
Methods Maternal pre-pregnancy BMI and estimated fat mass (from skinfold 
thicknesses) were related to asthma, wheeze and atopy in 940 children. Transient or 
persistent/late wheeze was classified using questionnaire data collected at ages 6, 12, 24 and 
36 months and 6 years. At 6 years, skin prick testing was conducted and exhaled nitric oxide 
and spirometry measured. Infant adiposity gain was calculated from skinfold thickness at 
birth and 6 months. 
Results Greater maternal BMI and fat mass were associated with increased childhood 
wheeze (RR 1.08 per 5 kg m-2, p=0.006; RR 1.09 per 10 kg, p=0.003); these reflected 
associations with transient wheeze (RR 1.11, p=0.003; RR 1.13, p=0.002, respectively) but 
not with persistent wheeze or asthma. Infant adiposity gain was associated with persistent 
wheeze but not significantly. Adjusting for infant adiposity gain or  BMI at 3 or 6 years did 
not reduce the association between maternal adiposity and transient wheeze. Maternal 
adiposity was not associated with offspring atopy, exhaled nitric oxide, or spirometry.  
Discussion Greater maternal adiposity is associated with transient wheeze but not asthma 
or atopy, suggesting effects upon airway structure/function but not allergic predisposition.   
Abstract Word count 250 
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What is the key question? Does maternal body composition influence the presence of 
asthma and wheeze phenotypes in children at age 6 years. 
What is the bottom line? This study uses directly measured BMI and estimated maternal fat 
mass to demonstrate an association between maternal obesity and the transient childhood 
wheeze phenotype. 
Why read on? This is the first study to investigate the association of prospectively measured 
of maternal body composition with longitudinal wheeze outcomes in childhood. 
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INTRODUCTION 
In recent decades westernised countries have experienced increases in both obesity and 
respiratory disease, including asthma. These changes may reflect causal links or shared 
environmental or genetic factors. Increased asthma and asthma-like symptoms have been 
reported in association with adult(1) and childhood obesity.(2) Mechanisms have been 
proposed attributing this to anatomical, inflammatory or immunological consequences of 
obesity.(3, 4) There is evidence that children of obese women are at increased risk of 
asthma(5, 6) and wheeze,(7, 8) suggesting maternal obesity may affect respiratory or immune 
development.  
 
Maternal pre-pregnancy weight has increased considerably in recent years, therefore potential 
adverse effects upon childhood health represent an important public health issue.(9) However, 
socioeconomic and lifestyle factors may confound the relationship between maternal 
adiposity and childhood wheeze.(10) Similarly, any such relationship may also be 
confounded by infant or childhood adiposity since maternal and child obesity are 
associated(11) and associations have been found between childhood obesity and asthma-like 
symptoms,(2) between rapid early weight gain and diminished infant lung function,(12) and 
between infant adiposity(13) or weight gain and early childhood wheeze.(13, 14) Further 
possible confounding factors include obesity-associated pregnancy complications such as 
preeclampsia, caesarean section, preterm birth and intrauterine growth restriction.(10, 15)  
 
Wheeze risk at 18 months has been shown to increase with increasing maternal pre-
pregnancy body mass index (BMI),(7) the contribution of pregnancy complications to this 
association was found to be small. Recently, an association between maternal pre-pregnancy 
BMI and current asthma in children at age 15-16 years was reported, suggesting that adverse 
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effects of maternal obesity might persist throughout childhood.(5) Although large, these 
studies used reported pre-pregnancy weight, and childhood lung function and atopy were not 
measured. Measures of fat mass may potentially represent maternal adiposity better than BMI. 
This study is the first to explore the relationship between maternal fat mass and childhood 
asthma and wheeze alongside objective measurements of atopy and lung function.  
 
 
METHODS 
Participants 
Participants were mothers and children from the Southampton Women’s Survey.(16) Women 
aged 20-34 years were recruited during 1998-2002. Women were interviewed and 
anthropometric measurements made at recruitment and, for those who became pregnant, at 11 
and 34 weeks of pregnancy. Childhood follow-up visits occurred at 6, 12, 24 and 36 months. 
During 2006-2010 1529 children aged 6 years were invited for respiratory follow-up. Home-
based questionnaire, skin test and spirometry data were collected from 940 children. 
Participants were encouraged to attend the clinic for exhaled nitric oxide (eNO) testing, 596 
did so but time and resources meant that not all participants attended. Maternal pre-pregnancy 
fat mass and BMI measurements were available for 927 (98.6 %) and 930 (98.9 %) women 
respectively (Figure 1). Parental consent was obtained and local ethical approval was granted 
(276/97, 307/97, 089/99, 06/Q1702/104).  
Maternal anthropometry  
Pre-pregnancy height and weight were measured using portable Seca 835 scales (Seca Ltd., 
Birmingham, UK) and Leicester stadiometer (Invicta Plastics Ltd., Leicester, UK). Biceps, 
triceps, suprailiac and subscapular skinfold thicknesses were measured with Harpenden ‘John 
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Bull’ calipers (British Indicates Ltd., St Albans, UK). A standard protocol requiring three 
readings within 10% was followed. BMI was calculated as weight (kg)/(height (m))2. Fat 
mass was estimated from body weight and skinfolds using the Durnin and Womersley 
equation.(17) Analysis was limited to pre-pregnancy measurements as body composition 
equations are not validated in pregnancy.  
Childhood anthropometry 
Research nurses measured subscapular skinfold thicknesses at birth and 6 months. 
Subscapular adiposity change conditional upon initial measurements was calculated using 
regression to account for exact age and regression to the mean. BMI at 3 and 6 years was 
calculated from height and weight and the values converted to age and gender specific z-
scores using the Child Growth Foundation 1990 Reference (London, UK). 
Atopy 
Skin prick testing was conducted at age 6 years using cat, dog, house dust mite 
(Dermatophagoides pteronyssinus), egg, milk, grass and tree pollen allergens. A positive 
control of >3mm and negative control of 0mm was required. Any response ≥3 mm was 
considered evidence of atopy.  
Childhood asthma and wheeze  
Research nurses administered ISAAC core-questionnaire wheezing-module questions.(18) 
Mothers were asked whether their child had ‘ever been diagnosed with asthma by a doctor’ or 
had experienced ‘any episodes of chestiness associated with wheezing or whistling in his/her 
chest since they were last seen?’ Children who had ever been diagnosed with asthma and had 
experienced asthma symptoms or received asthma medication within the last year were 
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considered to have current asthma; those reported to wheeze within the last year were 
considered to have current wheeze. Questionnaire data obtained at 6, 12, 24 and 36 months 
were combined with that from 6 years to define wheeze phenotypes based upon those of the 
Tuscon Children’s Respiratory Study(19): 
Transient wheeze: Wheeze  ≤3 years but no wheeze or asthma treatment at 6 years. 
Persistent wheeze: Wheeze ≤3 years plus wheeze or asthma treatment at 6 years. 
Late-onset wheeze: No wheeze ≤3 years but wheeze or asthma treatment at 6 years. 
Very few children had late-onset wheeze so the persistent and late-onset wheeze groups were 
combined.  
Lung function 
Spirometry was measured using a portable Koko spirometer with incentive software (KoKo 
v4; PDS Instrumentation; Louisville, USA). Measurements were made according to ATS 
guidelines,(20) although to avoid discomfort, nose-clips were not worn. Spirometry indices 
were standardised for height, gender and age using the growing lungs reference.(21) 
Exhaled nitric oxide 
Exhaled nitric oxide  was measured according to ERS/ATS recommendations using a NIOX® 
chemiluminescence analyser (Aerocrine, Sweden).(22) A mean of three readings was 
calculated where possible. Values were normalised by inverse square root transformation 
then standardised. The sign was reversed so that high standardised scores represent high 
untransformed eNO values. 
Statistical methods 
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Relative risks for binary outcomes were modelled using poisson regression with robust 
variance; poisson regression being appropriate for common outcomes where odds ratios 
cannot be interpreted as relative risks.(23) Children with transient or persistent/late wheeze 
were compared to children who had never wheezed. Linear regression was used for 
continuous outcomes. Relative risks and regression coefficients were expressed relative to 5 
kg m-2change in BMI or 10 kg change in fat mass. Analyses were also conducted considering 
Maternal BMI as a discrete variable to classify women according to the world health 
organisation scheme as either normal weight (BMI 18.5-24.99), overweight (BMI 25-29.99) 
or obese (BMI ≥ 30) and considering maternal weight gain in pregnancy according to 
Institute of Medicine categories. 
 
Potential confounders identified a priori were; maternal age, height, parity, education, 
socioeconomic status, smoking in pregnancy, asthma, eczema, rhinitis, and atopy and child’s 
gender, birthweight, gestation, and age at last breastfeed. Potential confounders were tested 
for association with each respiratory outcome. Model 1 included all variables associated with 
each outcome but excluded birth weight, gestation, adiposity gain in the first 6 months of life 
and the child’s BMI at age 6 years as each of these may lie on the causal pathway. Model 2 
included birthweight and gestation if they were significantly associated with the outcomes 
and further analyses were conducted adjusting for all significantly associated confounders 
(including birthweight and gestation) and infant adiposity gain (birth-6 months) (Model 3) 
and child’s BMI aged 6 (Model 4).  
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Based upon effect sizes of approaching 5% seen in previous studies we estimated 
approaching 100% power to detect an increase in risk of this magnitude per kg maternal fat 
mass and of 80-100% per BMI unit dependent upon physiological outcome. Bonferroni 
correction was considered over-conservative as the analyses were designed a priori to test a 
limited number of hypotheses and not all the tests were independent.(24) We focused our 
interest on results with P-values ≤0.01 and considered consistency of the findings in our 
interpretation. Stata® 11 (Stata Corp., College Station, TX) was used for all analyses. 
 
RESULTS 
Participants 
Participating mothers were similar to non-participants in terms of body composition, asthma 
and atopy, however, they were slightly older, taller, less likely to smoke in pregnancy, more 
likely to be primiparous and were of higher educational attainment and social class. 
Participating children were of similar birthweight and gestation compared with those not 
followed up (Table 1). When compared with the children attending the clinic, children unable 
to attend did not differ significantly (data not shown). 
 
The median (IQR) maternal BMI was 24.3 (22.0–27.5) kg m-2; 261 (28.1%) mothers were 
overweight and 135 (14.5%) were obese. Median maternal pre-pregnancy fat mass was 20.3 
(16.3–25.9) kg. The median period between recruitment and 11 week interviews was 67 
weeks (32-106 weeks). The mean (SD) difference in BMI calculated from weight measured 
at 11 weeks’ gestation was 0.62 (1.62) kg m-2greater than that calculated from weight 
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measured at recruitment, whilst BMI calculated from the weight that mothers self-reported at 
11 weeks of pregnancy to have been their immediate pre-pregnancy weight was 0.34 (1.78) 
kg m-2 less than that calculated from weight measured at recruitment; the respective 
correlation coefficients were 0.95 and 0.93. Both maternal BMI and maternal fat mass were 
positively associated with child’s birthweight (p<0.001), there was no significant association 
with infant adiposity change. 
Wheeze was experienced by 559 children (59.9%), and 137 (14.6%) had wheeze at age six 
years. Wheezing was transient in 401 (42.9 %) and persistent/late in 158 children (16.9%) 
(Figure 1). Asthma had been diagnosed in 145 children (15.4%), of whom 100 (10.6 %) had 
current symptoms or asthma treatment. Technically acceptable spirometry was achieved by 
804 children (85.5%); 489 (82.0%) of 596 children attending the clinic had acceptable eNO 
measurements (Figure 1). 
Childhood wheeze 
Maternal pre-pregnancy fat mass was positively associated with ever wheezing (RR 1.09 per 
10 kg, p=0.003). This association remained after adjusting for potential confounders (RR 
1.08 per 10 kg, p=0.007 - Model 1, basic confounders); results were similar when gestation, 
infant adiposity gain or child’s BMI aged 6 years where included in the model (Table 2). 
Maternal fat mass was not associated with current or ever asthma. Children experiencing 
wheeze ≤3 years appeared to account for most of the association between maternal fatness 
and ever wheezing as maternal fat mass was positively associated with transient wheeze (RR 
1.13, p=0.002) but not with current or persistent wheeze. The association with transient 
wheeze remained after adjusting for potential confounders, gestation, infant adiposity gain 
and child’s BMI aged 6 years (Table 2, Models 1-4) and also when child’s BMI aged 3 was 
adjusted for (RR 1.01, p=0.02). 
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Similar associations were found between maternal pre-pregnancy BMI and wheeze outcomes 
(Table 3). Maternal BMI was positively associated with ever wheezing (RR 1.08 per 5 kg m-2, 
p=0.006) and transient wheeze (RR 1.11 per 5 kg m-2, p=0.003). These associations remained 
in each of the four adjusted models. Maternal BMI was not associated with ever or current 
asthma or current or persistent wheeze.  
Maternal weight gain was not associated with respiratory outcome in the children (Tables S1 
& S2). 
 
Childhood atopy 
Neither maternal fat mass (Table 2) nor BMI (Table 3) were associated with cutaneous 
sensitisation, before or after adjusting for confounders. 
 
Lung function and eNO 
Neither maternal fat mass nor BMI were associated with any measure of lung function, 
(Table 4). There were no associations after adjusting for confounders in any multivariable 
model. No associations, before or after adjustment, were found between either maternal fat 
mass or maternal BMI and eNO (Table S3).  
All the above results for wheeze, atopy, lung function and eNO were unchanged by 
considering BMI as a categorical variable or by limiting the analysis to women who became 
pregnant within 1 year of their initial interview. 
Infant adiposity gain  
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Infant adiposity gain was associated with persistent wheeze but significance was reduced 
after adjusting for likely confounders (RR 1.14, p=0.05). Similar results were seen after other 
potential confounders were adjusted for: gestation (RR 1.14, p=0.04 – Model 2), BMI aged 3 
years (RR 1.10, p=0.16 – Model 3) and BMI aged 6 years (RR 1.14, p=0.05 – Model 4). 
There were no significant associations with ever or current asthma, or ever or current wheeze. 
In contrast to the findings for maternal obesity, no association was found between infant 
adiposity gain and transient wheeze (Table S4). There were weak inverse associations 
between infant adiposity gain and both FEF25-75% and FEV1/FVC (p=0.02 for each) (Table 
S5).  
DISCUSSION 
This is the first study to measure the association between pre-pregnancy measurements of 
maternal adiposity and longitudinal childhood wheeze phenotypes. Greater maternal fat mass 
and BMI were associated with increased childhood wheeze risk. There were significant 
positive associations with transient wheeze but none with persistent wheeze or asthma. This 
has potentially important public health implications since individuals who wheeze in infancy 
more commonly develop chronic obstructive airways disease as adults. Adjusting for infant 
adiposity or child’s BMI at age 3 or 6 years did not reduce the association with transient 
wheeze. There were no associations between maternal fatness and atopy, eNO or spirometry.  
 
Previous studies have used BMI to estimate adiposity. Women were recruited after 
conception and pre-pregnancy weight self-reported often several months after birth;(6) in 
some studies neither height nor weight was measured.(7)To provide an objective measure of 
adiposity, uncomplicated by variation in BMI with body type(25) or by alterations in fat 
distribution during pregnancy(26) we estimated maternal fat mass from pre-pregnancy 
skinfold thicknesses. BMI calculated from weight measured pre-pregnancy  and from 
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estimated pre-pregnancy weight self-reported at 11 weeks of pregnancy were closely 
correlated. Moreover, the study’s main findings were unchanged by restricting analyses to 
women for whom less than a year had elapsed between initial and pregnancy interviews. 
Together these findings suggest that the measured pre-pregnancy values are likely to 
accurately reflect relative maternal fatness immediately before and during early pregnancy. 
 
The finding of increased wheeze in association with greater maternal adiposity is consistent 
with previous studies. Associations have been found between higher maternal BMI and 
increased wheeze at 18 months,(7) 3 years (8, 27) and 8 years,(6) and also in adolescence.(5)  
Few studies have assessed objective measures of atopy in relation to maternal adiposity. 
Kumar et al found an inverse relationship between maternal pre-pregnancy BMI and cord 
blood total IgE but no association with food allergy or eczema,(8) whilst Scholtens et al 
found no association with specific IgE to inhalant allergens.(6) We have found neither an 
association between maternal adiposity and cutaneous sensitisation nor eosinophilic airway 
inflammation measured by eNO. Furthermore, although cross-sectional adult data have 
suggested an association between adiposity and atopy,(28) cross-sectional studies in 
childhood provide no evidence for this.(29)  
 
The positive association between maternal adiposity and transient wheeze is unique to this 
study as no other study has assessed longitudinal wheeze phenotypes. Our finding is 
supported by studies assessing wheeze in early childhood.(7, 8, 27) The lack of longitudinal 
studies means that evidence supporting an association between maternal adiposity and 
persistence of wheeze symptoms in older children is less conclusive. No association was 
found between maternal adiposity and doctor-diagnosed asthma in our study, although our 
power was less for this outcome than for transient or for ever wheeze. The only study to date 
to have found such an association, did so in infancy when asthma is difficult to diagnose.(27) 
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Two studies(5, 6) have reported associations with self-reported asthma, although only after 
considering effect modification by genetic predisposition. However these studies’ results 
were contradictory; Scholtens found maternal adiposity associated with asthma only in 
children considered predisposed due to parental asthma or allergy,(6) whilst Patel found this 
association to be strongest in children without a parental history of atopy.(5) Subtle 
differences in the phenotypic characteristics of the individuals assigned to the current wheeze 
grouping may have existed between the populations and age groups considered in each of 
these studies. Similarly differences in the nature and extent of residual confounding 
associated with the measured or estimated values of maternal adiposity used may explain, in 
part, the conflicting results. 
 
Previous studies report an effect of maternal adiposity beyond that mediated by pregnancy or 
birth complications,(7) whilst this and other studies suggest that a direct effect beyond that of 
an association with childhood obesity is possible. We were unable to confirm our previous 
finding of increased wheeze risk in association with greater infant adiposity gain,(13) 
possibly due to reduced power as fewer children were seen at 6 than at 3 years. Nevertheless 
it was felt important to correct for potential confounding by infant adiposity gain. Adjustment 
for infant adiposity gain or childhood BMI did not reduce the association between maternal 
adiposity and transient wheeze, suggesting that the effect of maternal obesity is not mediated 
by childhood adiposity. Indeed the contrasting findings of an association between maternal 
obesity and transient wheeze and a borderline association between infant weight gain and 
persistent wheeze suggests separate mechanisms may underlie these associations.  
 
This study did not detect any association between maternal pregnancy weight gain, according 
to Institute of Medicine categorisation, and any wheeze, atopy or lung function outcome. This 
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is surprising given that excessive pregnancy weight gain has been shown to be associated 
with infant adiposity and has been proposed to predispose to a number of obesity-associated 
adverse outcomes.(30) Possibly, categorisation according to weight gain throughout 
pregnancy is not sensitive to the effects of weight gain during periods of particular 
significance for determining fetal health and development. Alternatively, absolute maternal 
fatness may determine fetal exposure and childhood outcome more directly than rate of 
weight gain. Serum levels of proinflammatory cytokines are known to be higher in obese 
pregnant women than pregnant women of normal weight(31) and it has been proposed that an 
increased inflammatory response might affect fetal immunological or pulmonary 
development. Other factors associated with obesity include high glucose, insulin, lipid and 
leptin levels.(4, 32) Although observational studies cannot determine causality, careful 
characterisation of wheeze phenotypes may suggest mechanisms by which maternal adiposity 
might predispose to childhood wheeze. In the absence of an association with atopy, there is 
little to support an effect of maternal adiposity upon atopic immunity.  
 
Transient childhood wheeze is believed to arise during viral infections in individuals 
predisposed to airways obstruction. It is possible that maternal obesity might affect airway 
development. Leptin is elevated in obesity(32) and leptin receptors in the lung may mediate 
effects upon lung growth.(33) However, although lung function is believed to track across the 
life-course, no association was found between maternal adiposity and spirometry at 6 years. 
This may reflect a transient effect upon lung function or there may be subtle differences in 
airway function that the spirometric indices measured could not detect. It is possible that lung 
function effects are particularly important in the transient wheeze phenotype and that a 
significant association may be found in a cohort large enough to support analysis of the 
relationship between adiposity and lung function stratified by wheeze phenotype. 
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Alternatively, maternal adiposity may confer vulnerability to transient wheeze via an effect 
upon severity of viral infection, perhaps by an effect upon innate immunity similar to that 
proposed to explain reported associations between prenatal vitamin D exposure and 
childhood wheeze.(34) Certainly there is data to support increased respiratory infection in 
overweight individuals.(35)  
 
This study’s strength lies in the robust measurement of maternal fat mass and BMI in a 
longitudinal birth-cohort. The wheeze outcomes were assessed using standardised questions 
permitting comparison with other studies. Uniquely, this study considered the influence of 
early infant adiposity gain upon outcome and also objectively assessed lung function and skin 
sensitisation. Although observational studies are inherently vulnerable to response bias, the 
response rate was good in this study and neither maternal pre-pregnancy fat mass nor BMI 
differed significantly between participants and non-participants. Furthermore, the relationship 
between maternal adiposity and childhood wheeze was one of many objectives of a broader 
study assessing the effect of maternal nutrition upon childhood growth and health, it is 
unlikely that parental health knowledge may have affected participation. A hurdle to 
interpreting the data surrounds identifying the relevant exposure. Ideally measurements might 
be taken in early pregnancy rather than pre-pregnancy, but changes to maternal body 
composition vary between women and there are no standardised measurements or reference 
charts for pregnancy. Critical windows in pregnancy may also be relevant. Despite these 
challenges we find that the association with wheeze holds whether measuring BMI or 
adiposity estimated from skin fold thickness prior to pregnancy. 
 
In conclusion, we found that greater maternal pre-pregnancy fat mass and BMI were 
associated with an increased risk of transient wheeze in childhood. There was no evidence for 
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an effect of maternal adiposity upon childhood atopy but the association with transient 
wheeze suggests an effect upon airway development. 
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Figure and table legends 
Figure 1 Flow of participants through the study 
Table 1 Comparison of SWS mother-child pairs with complete data with those lacking either 
maternal body composition or 6-year follow-up data but born in the same time period. 
Table 2 Relationship between maternal pre-pregnancy fat mass (kg) and wheeze and atopy 
phenotypes in the offspring at age 6 years. 
Table 3 Relationship between maternal pre-pregnancy BMI and wheeze and atopy 
phenotypes in the offspring at age 6 years. 
Table 4 Relationship between maternal pre-pregnancy fat mass (kg) and exhaled nitric oxide 
and lung function in the offspring at age 6 years. 
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Table 1 Comparison of SWS mother-child pairs with complete data with those lacking either 
maternal body composition or 6-year follow-up data but born in the same time period. 
 Participating 
mother-child 
pairs (n= 940) 
Mother-child 
pairs with missing 
data (n=589) 
P-value 
Maternal characteristics    
Age at child’s birth, years (mean (SD)) 30.3 (3.8) 29.7 (3.8) 0.007 
Primiparous (n (%))    
No 494 (52.6) 355 (60.3) 0.003 
Yes 446 (47.5) 234 (39.7)  
Qualifications 
(n (%)) 
None  15 (1.6) 36 (6.1) <0.001 
GCSE D-G 88 (9.4) 67 (11.4)  
GCSE A*-C 278 (29.6) 165 (28.1)  
 A Level 270 (28.8) 175 (29.8)  
 HND 66 (7.0) 39 (6.6)  
 Degree 222 (23.6) 106 (18.0)  
Parents’ social class 
(n (%)) 
I 100 (10.8) 52 (12.3) 0.019 
II 454 (48.8) 178 (42.3)  
 IIIN 263 (28.5) 112 (26.6)  
 IIIM 72 (7.7) 51 (12.1)  
 IV 39 (4.2) 20 (4.8)  
 V 2 (0.2) 8 (1.9)  
Smoked in pregnancy (n (%))    
No 768 (84.9) 431 (77.2) <0.001 
Yes 137 (15.1) 127 (22.8)  
Maternal asthma (n (%))    
No 733 (78.7) 442 (76.2) 0.251 
Yes 198 (21.3) 138 (23.8)  
Maternal childhood eczema (n (%))    
No 758 (81.5) 476 (82.1) 0.783 
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Yes 172 (18.5) 104 (17.9)  
Maternal rhinitis (n (%))    
No 539 (57.9) 353 (60.9) 0.254 
Yes 392 (42.1) 227 (39.1)  
Maternal atopy (n (%))    
No 438 (53.0) 236 (57.0) 0.185 
Yes 388 (47.0) 178 (43.0)  
Height, cm (mean (SD)) 163.5 (6.6) 162.7 (6.0) 0.020 
BMI, kg/m2 (median, (IQR)) 24.3 (22.0 – 27.5) 24.1 (21.8 – 27.4) 0.657 
Fat mass, kg (median, (IQR)) 20.3 (16.3 – 25.9) 19.5 (15.7 – 25.8) 0.116 
Child’s characteristics     
Gender (n (%))    
Male 485 (51.6) 313 (53.4) 0.489 
Female 455 (48.4) 273 (46.6)  
Birth weight, kg (mean (SD)) 3.440 (0.551) 3.420 (0.580) 0.615 
Gestational age, weeks (median 
(IQR)) 
40.1 (39.0 – 41.0) 40.0 (39.1 – 41.0) 0.969 
Mother smoked during child’s infancy  
(n (%)) 
   
No 768 (84.9) 431 (77.2) <0.001 
Yes 137 (15.1) 125 (22.8)  
Numbers do not always add to the full column totals due to missing data 
Binary outcomes were compared by χ2 test, categorical outcomes by a χ2 test for trend, and 
continuous variables using t-tests, after transformation where appropriate, or a ranksum test. 
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Table 2 Relationship between maternal pre-pregnancy fat mass (kg) and wheeze and atopy phenotypes in the offspring at age 6 years  
 
Unadjusted analysis Model 1 Model 2 
Outcome RR (95% CI) P-value n RR (95% CI) P-value n RR (95% CI) P-value n 
Ever wheeze 1.09 (1.03, 1.16) 0.003 921 1.08 (1.02, 1.15) 0.007 895 1.09 (1.03, 1.16) 0.002 895 
Ever asthma 1.10 (0.93, 1.31) 0.27 927 1.05 (0.89, 1.24) 0.57 890 1.10 (0.93, 1.30) 0.28 890 
Current wheeze 1.04 (0.86, 1.25) 0.68 927 1.06 (0.87, 1.29) 0.54 808 1.09 (0.90, 1.32) 0.39 808 
Current asthma 1.14 (0.91, 1.43) 0.24 927 1.10 (0.89, 1.37) 0.39 918 1.14 (0.92, 1.41) 0.22 918 
Transient wheeze 1.13 (1.05, 1.23) 0.002 764 1.11 (1.02, 1.20) 0.01 743 1.12 (1.03, 1.21) 0.006 743 
Persistent wheeze 1.12 (0.96, 1.30) 0.14 526 1.08 (0.94, 1.24) 0.26 519 1.11 (0.98, 1.27) 0.11 519 
Atopy 1.07 (0.91, 1.25) 0.43 681 1.14 (0.97, 1.35) 0.12 590 1.14 (0.97, 1.35) 0.12 590 
     Model 3 Model 4 
     RR (95% CI) P-value n RR (95% CI) P-value n 
Ever wheeze     1.1 (1.03, 1.17) 0.004 817 1.09 (1.03, 1.15) 0.004 893 
Ever asthma     1.14 (0.96, 1.35) 0.13 823 1.06 (0.89, 1.28) 0.52 888 
Current wheeze     1.03 (0.84, 1.28) 0.76 741 1.09 (0.89, 1.33) 0.40 806 
Current asthma     1.17 (0.94, 1.45) 0.16 835 1.14 (0.91, 1.42) 0.27 915 
Transient wheeze     1.11 (1.02, 1.21) 0.01 686 1.11 (1.02, 1.20) 0.01 741 
Persistent wheeze     1.12 (0.97, 1.30) 0.13 478 1.10 (0.96, 1.27) 0.17 519 
Atopy     1.21 (1.02, 1.44) 0.03 546 1.15 (0.97, 1.36) 0.12 590 
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Relative risk represents change in outcome per 10 kg of maternal pre-pregnancy fat mass.  
Model 1 Adjusted for potential confounders significantly associated with the outcome, excluding child’s birthweight, gestation. 
Ever wheeze-maternal education, asthma and rhinitis, child’s gender and age last breastfed; Ever asthma- maternal education, asthma and smoking in 
pregnancy, and child’s gender; Current wheeze-maternal education, asthma and atopy; Current asthma-maternal education and asthma; Transient wheeze-
maternal height, parity, asthma and rhinitis, child’s gender and age last breastfed; Persistent wheeze-maternal education, asthma and rhinitis and child’s 
gender; Atopy-maternal social class, asthma and atopy, and child’s gender. 
Model 2 adjusted for potential confounders significantly associated with the outcome, including child’s birthweight, gestation. 
Ever wheeze-maternal education, asthma and rhinitis, child’s gender, age last breastfed and gestation; Ever asthma- maternal education, asthma, smoking 
in pregnancy and parity, child’s gender and gestation; Current wheeze-maternal education, asthma and atopy, child’s gender and gestation; Current 
asthma-maternal education and asthma, and child’s gestation; Transient wheeze-maternal height, parity, asthma and rhinitis, child’s gender, age last 
breastfed and gestation; Persistent wheeze-maternal education, asthma and rhinitis, child’s gender and gestation; Atopy-maternal social class, asthma and 
atopy, and child’s gender. 
Model 3 adjusted for increase in adiposity between birth and 6 months and potential confounders significantly associated with the outcome (listed in 
Model 2) including child’s birthweight and gestation. 
Model 4 adjusted for child’s BMI at age 6 years and potential confounders significantly associated with the outcome including child’s birthweight and 
gestation. 
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Table 3 Relationship between maternal pre-pregnancy BMI and wheeze and atopy phenotypes in the offspring at age 6 years  
 
Unadjusted analysis Model 1 Model 2 
Outcome RR (95% CI) P-value n RR (95% CI) P-value n RR (95% CI) P-value n 
Ever wheeze 1.08 (1.02, 1.14) 0.006 924 1.07 (1.01, 1.12) 0.01 897 1.08 (1.02, 1.13) 0.004 897 
Ever asthma 1.07 (0.92, 1.24) 0.4 930 1.02 (0.87, 1.18) 0.84 892 1.06 (0.91, 1.24) 0.44 892 
Current wheeze 0.99 (0.85, 1.16) 0.94 930 0.99 (0.84, 1.17) 0.94 809 1.02 (0.87, 1.20) 0.79 809 
Current asthma 1.10 (0.91, 1.33) 0.31 930 1.06 (0.88, 1.27) 0.53 920 1.10 (0.92, 1.32) 0.30 920 
Transient wheeze 1.11 (1.04, 1.18) 0.003 767 1.10 (1.03, 1.17) 0.006 746 1.11 (1.04, 1.18) 0.002 746 
Persistent wheeze 1.08 (0.95, 1.24) 0.22 527 1.05 (0.93, 1.20) 0.42 519 1.09 (0.97, 1.24) 0.16 519 
Atopy 1.08 (0.94, 1.24) 0.31 681 1.13 (0.98, 1.31) 0.10 589 1.13 (0.98, 1.31) 0.1 589 
     Model3 Model 4 
     RR (95% CI) P-value n RR (95% CI) P-value n 
Ever wheeze     1.08 (1.02, 1.14) 0.009 819 1.07 (1.02, 1.13) 0.01 895 
Ever asthma     1.08 (0.92, 1.26) 0.34 825 1.02 (0.86, 1.20) 0.85 890 
Current wheeze     0.97 (0.82, 1.16) 0.77 742 1.02 (0.86, 1.22) 0.79 807 
Current asthma     1.10 (0.91, 1.33) 0.31 837 1.10 (0.90, 1.34) 0.35 917 
Transient wheeze     1.10 (1.03, 1.18) 0.006 689 1.10 (1.03, 1.18) 0.007 744 
Persistent wheeze     1.09 (0.95, 1.25) 0.23 478 1.08 (0.95, 1.23) 0.25 519 
Atopy     1.17 (1.00, 1.36) 0.05 545 1.14 (0.98, 1.32) 0.09 589 
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Relative risk represents change in outcome per 5 kg m-2of maternal pre-pregnancy BMI. 
Models 1-4 adjusted for confounders as described in Table 2. 
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Table 4 Relationship between maternal pre-pregnancy fat mass (kg) and exhaled nitric oxide and lung function in the offspring at age 6 years  
 Unadjusted analysis Model 1 Model 2 
 Beta (95% CI) P-value n Beta (95% CI) P-value n Beta (95% CI) P-value n 
FEV1 z-score 0.0349 (-0.0413, 0.1111) 0.37 793 0.0274 (-0.0476, 0.1025) 0.47 793 0.0230 (-0.0555, 0.1015) 0.56 784 
FVC z-score 0.0433 (-0.0439, 0.1306) 0.33 793 0.0301 (-0.0586, 0.1188) 0.5 765 0.0301 (-0.0586, 0.1188) 0.5 765 
FEF25-75% z-score 0.0163 (-0.0796, 0.1122) 0.74 793 0.0181 (-0.0775, 0.1137) 0.71 793 0.0071 (-0.0886, 0.1028) 0.88 793 
FEV1/FVC z-score -0.0190 (-0.1043, 0.0663) 0.66 793 -0.0130 (-0.0998, 0.0739) 0.77 765 -0.0130 (-0.0998, 0.0739) 0.77 765 
Exhaled nitric oxide -0.0575 (-0.1667, 0.0517) 0.30 482 -0.0908 (-0.2018, 0.0203) 0.11 477 -0.0908 (-0.2018, 0.0203) 0.11 477 
     Model 3 Model 4 
     Beta (95% CI) P-value n Beta (95% CI) P-value n 
FEV1 z-score     0.0115 (-0.0702, 0.0932) 0.78 721 0.0122 (-0.0684, 0.0928) 0.76 784 
FVC z-score     0.0287 (-0.0625, 0.1199) 0.54 713 0.0001 (-0.0913, 0.0916) 0.99 765 
FEF25-75% z-score     -0.0035 (-0.1031, 0.0961) 0.94 725 0.0160 (-0.0829, 0.1149) 0.75 793 
FEV1/FVC z-score     -0.0293 (-0.1181, 0.0594) 0.51 713 0.0055 (-0.0846, 0.0956) 0.9 765 
Exhaled nitric oxide     -0.0989 (-0.2152, 0.0174) 0.09 434 -0.0889 (-0.2029, 0.0250) 0.12 477 
 
Regression coefficient represents change in outcome per 10 kg of maternal pre-pregnancy fat mass. 
Model 1 Adjusted for potential confounders significantly associated with the outcome, excluding child’s birthweight and gestation. 
FEV1-child’s gender; FVC-maternal smoking in pregnancy and rhinitis, and child’s gender; FEF25-75%-maternal parity and child’s gender; FEV1/FVC-maternal 
rhinitis, eczema, smoking in pregnancy and parity; eNO-maternal height, asthma and eczema. 
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Model 2 adjusted for potential confounders significantly associated with the outcome, including child’s birthweight and gestation. 
FEV1-maternal height, and child’s gender and birthweight; FVC-maternal smoking in pregnancy and rhinitis, and child’s gender; FEF25-75%-maternal parity and 
child’s gender and gestation; FEV1/FVC-maternal rhinitis, eczema, smoking in pregnancy and parity; eNO-maternal height, asthma and eczema. 
Model 3 adjusted for increase in adiposity between birth and 6 months and potential confounders significantly associated with the outcome including 
child’s birthweight and gestation (listed in Model 2). 
Model 4 adjusted for child’s BMI at age 6 years and potential confounders significantly associated with the outcome including child’s birthweight and 
gestation (listed in Model 2). 
